nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—Ezetimibe—atherosclerosis	0.205	0.279	CbGbCtD
Naltrexone—UGT1A1—Simvastatin—atherosclerosis	0.19	0.26	CbGbCtD
Naltrexone—UGT1A1—Lovastatin—atherosclerosis	0.186	0.254	CbGbCtD
Naltrexone—ABCB1—Ezetimibe—atherosclerosis	0.0406	0.0554	CbGbCtD
Naltrexone—ABCB1—Simvastatin—atherosclerosis	0.0377	0.0515	CbGbCtD
Naltrexone—ABCB1—Lovastatin—atherosclerosis	0.0369	0.0504	CbGbCtD
Naltrexone—ABCB1—Pravastatin—atherosclerosis	0.0369	0.0504	CbGbCtD
Naltrexone—Naloxone—TLR4—atherosclerosis	0.00236	0.711	CrCbGaD
Naltrexone—Naloxone—ESR1—atherosclerosis	0.000662	0.2	CrCbGaD
Naltrexone—Confusional state—Rosuvastatin—atherosclerosis	0.000471	0.0025	CcSEcCtD
Naltrexone—Back pain—Lovastatin—atherosclerosis	0.000469	0.00249	CcSEcCtD
Naltrexone—Flatulence—Ezetimibe—atherosclerosis	0.000469	0.00249	CcSEcCtD
Naltrexone—Pharyngitis—Pravastatin—atherosclerosis	0.000467	0.00248	CcSEcCtD
Naltrexone—Chills—Simvastatin—atherosclerosis	0.000467	0.00248	CcSEcCtD
Naltrexone—Muscle spasms—Lovastatin—atherosclerosis	0.000466	0.00248	CcSEcCtD
Naltrexone—Infection—Rosuvastatin—atherosclerosis	0.000464	0.00247	CcSEcCtD
Naltrexone—Alopecia—Simvastatin—atherosclerosis	0.00046	0.00245	CcSEcCtD
Naltrexone—Back pain—Ezetimibe—atherosclerosis	0.00046	0.00244	CcSEcCtD
Naltrexone—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000458	0.00243	CcSEcCtD
Naltrexone—Muscle spasms—Ezetimibe—atherosclerosis	0.000457	0.00243	CcSEcCtD
Naltrexone—Vision blurred—Lovastatin—atherosclerosis	0.000457	0.00243	CcSEcCtD
Naltrexone—Mental disorder—Simvastatin—atherosclerosis	0.000456	0.00243	CcSEcCtD
Naltrexone—Tremor—Lovastatin—atherosclerosis	0.000454	0.00241	CcSEcCtD
Naltrexone—Ill-defined disorder—Lovastatin—atherosclerosis	0.00045	0.00239	CcSEcCtD
Naltrexone—Eye disorder—Niacin—atherosclerosis	0.000447	0.00238	CcSEcCtD
Naltrexone—Flatulence—Simvastatin—atherosclerosis	0.000447	0.00237	CcSEcCtD
Naltrexone—Tinnitus—Niacin—atherosclerosis	0.000446	0.00237	CcSEcCtD
Naltrexone—Dysgeusia—Simvastatin—atherosclerosis	0.000444	0.00236	CcSEcCtD
Naltrexone—Angioedema—Lovastatin—atherosclerosis	0.000443	0.00235	CcSEcCtD
Naltrexone—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000441	0.00234	CcSEcCtD
Naltrexone—Tinnitus—Pravastatin—atherosclerosis	0.000439	0.00233	CcSEcCtD
Naltrexone—Malaise—Lovastatin—atherosclerosis	0.000437	0.00232	CcSEcCtD
Naltrexone—Cardiac disorder—Pravastatin—atherosclerosis	0.000437	0.00232	CcSEcCtD
Naltrexone—Muscle spasms—Simvastatin—atherosclerosis	0.000436	0.00232	CcSEcCtD
Naltrexone—Angioedema—Ezetimibe—atherosclerosis	0.000435	0.00231	CcSEcCtD
Naltrexone—Angiopathy—Niacin—atherosclerosis	0.000434	0.00231	CcSEcCtD
Naltrexone—Chills—Niacin—atherosclerosis	0.000429	0.00228	CcSEcCtD
Naltrexone—Malaise—Ezetimibe—atherosclerosis	0.000429	0.00228	CcSEcCtD
Naltrexone—Vision blurred—Simvastatin—atherosclerosis	0.000427	0.00227	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000425	0.00226	CcSEcCtD
Naltrexone—Tremor—Simvastatin—atherosclerosis	0.000425	0.00226	CcSEcCtD
Naltrexone—Alopecia—Niacin—atherosclerosis	0.000423	0.00225	CcSEcCtD
Naltrexone—Chills—Pravastatin—atherosclerosis	0.000423	0.00225	CcSEcCtD
Naltrexone—Insomnia—Rosuvastatin—atherosclerosis	0.000422	0.00224	CcSEcCtD
Naltrexone—Ill-defined disorder—Simvastatin—atherosclerosis	0.000421	0.00224	CcSEcCtD
Naltrexone—Palpitations—Ezetimibe—atherosclerosis	0.00042	0.00223	CcSEcCtD
Naltrexone—Paraesthesia—Rosuvastatin—atherosclerosis	0.000419	0.00223	CcSEcCtD
Naltrexone—Malnutrition—Niacin—atherosclerosis	0.000416	0.00221	CcSEcCtD
Naltrexone—Alopecia—Pravastatin—atherosclerosis	0.000416	0.00221	CcSEcCtD
Naltrexone—Cough—Ezetimibe—atherosclerosis	0.000415	0.00221	CcSEcCtD
Naltrexone—Angioedema—Simvastatin—atherosclerosis	0.000414	0.0022	CcSEcCtD
Naltrexone—Myalgia—Lovastatin—atherosclerosis	0.000413	0.00219	CcSEcCtD
Naltrexone—Chest pain—Lovastatin—atherosclerosis	0.000413	0.00219	CcSEcCtD
Naltrexone—Arthralgia—Lovastatin—atherosclerosis	0.000413	0.00219	CcSEcCtD
Naltrexone—Anxiety—Lovastatin—atherosclerosis	0.000411	0.00219	CcSEcCtD
Naltrexone—Hypertension—Ezetimibe—atherosclerosis	0.000411	0.00218	CcSEcCtD
Naltrexone—Flatulence—Niacin—atherosclerosis	0.00041	0.00218	CcSEcCtD
Naltrexone—Malaise—Simvastatin—atherosclerosis	0.000409	0.00217	CcSEcCtD
Naltrexone—Tension—Niacin—atherosclerosis	0.000409	0.00217	CcSEcCtD
Naltrexone—Discomfort—Lovastatin—atherosclerosis	0.000408	0.00217	CcSEcCtD
Naltrexone—Arthralgia—Ezetimibe—atherosclerosis	0.000405	0.00215	CcSEcCtD
Naltrexone—Chest pain—Ezetimibe—atherosclerosis	0.000405	0.00215	CcSEcCtD
Naltrexone—Myalgia—Ezetimibe—atherosclerosis	0.000405	0.00215	CcSEcCtD
Naltrexone—Nervousness—Niacin—atherosclerosis	0.000404	0.00215	CcSEcCtD
Naltrexone—Flatulence—Pravastatin—atherosclerosis	0.000404	0.00215	CcSEcCtD
Naltrexone—Dry mouth—Lovastatin—atherosclerosis	0.000404	0.00215	CcSEcCtD
Naltrexone—Tension—Pravastatin—atherosclerosis	0.000402	0.00214	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000402	0.00214	CcSEcCtD
Naltrexone—Dysgeusia—Pravastatin—atherosclerosis	0.000402	0.00213	CcSEcCtD
Naltrexone—Muscle spasms—Niacin—atherosclerosis	0.0004	0.00213	CcSEcCtD
Naltrexone—Discomfort—Ezetimibe—atherosclerosis	0.0004	0.00213	CcSEcCtD
Naltrexone—Constipation—Rosuvastatin—atherosclerosis	0.000399	0.00212	CcSEcCtD
Naltrexone—Pain—Rosuvastatin—atherosclerosis	0.000399	0.00212	CcSEcCtD
Naltrexone—Confusional state—Lovastatin—atherosclerosis	0.000399	0.00212	CcSEcCtD
Naltrexone—Nervousness—Pravastatin—atherosclerosis	0.000398	0.00212	CcSEcCtD
Naltrexone—Dry mouth—Ezetimibe—atherosclerosis	0.000396	0.0021	CcSEcCtD
Naltrexone—Anaphylactic shock—Lovastatin—atherosclerosis	0.000396	0.0021	CcSEcCtD
Naltrexone—Muscle spasms—Pravastatin—atherosclerosis	0.000394	0.00209	CcSEcCtD
Naltrexone—Infection—Lovastatin—atherosclerosis	0.000393	0.00209	CcSEcCtD
Naltrexone—Vision blurred—Niacin—atherosclerosis	0.000392	0.00209	CcSEcCtD
Naltrexone—Confusional state—Ezetimibe—atherosclerosis	0.000391	0.00208	CcSEcCtD
Naltrexone—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000388	0.00206	CcSEcCtD
Naltrexone—Vision blurred—Pravastatin—atherosclerosis	0.000386	0.00205	CcSEcCtD
Naltrexone—Arthralgia—Simvastatin—atherosclerosis	0.000386	0.00205	CcSEcCtD
Naltrexone—Myalgia—Simvastatin—atherosclerosis	0.000386	0.00205	CcSEcCtD
Naltrexone—Chest pain—Simvastatin—atherosclerosis	0.000386	0.00205	CcSEcCtD
Naltrexone—Infection—Ezetimibe—atherosclerosis	0.000386	0.00205	CcSEcCtD
Naltrexone—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000385	0.00204	CcSEcCtD
Naltrexone—Anxiety—Simvastatin—atherosclerosis	0.000385	0.00204	CcSEcCtD
Naltrexone—Tremor—Pravastatin—atherosclerosis	0.000384	0.00204	CcSEcCtD
Naltrexone—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000382	0.00203	CcSEcCtD
Naltrexone—Discomfort—Simvastatin—atherosclerosis	0.000381	0.00203	CcSEcCtD
Naltrexone—Nervous system disorder—Ezetimibe—atherosclerosis	0.000381	0.00202	CcSEcCtD
Naltrexone—Angioedema—Niacin—atherosclerosis	0.000381	0.00202	CcSEcCtD
Naltrexone—Ill-defined disorder—Pravastatin—atherosclerosis	0.00038	0.00202	CcSEcCtD
Naltrexone—Anorexia—Lovastatin—atherosclerosis	0.000377	0.002	CcSEcCtD
Naltrexone—Skin disorder—Ezetimibe—atherosclerosis	0.000377	0.002	CcSEcCtD
Naltrexone—Angioedema—Pravastatin—atherosclerosis	0.000375	0.00199	CcSEcCtD
Naltrexone—Syncope—Niacin—atherosclerosis	0.000373	0.00198	CcSEcCtD
Naltrexone—Confusional state—Simvastatin—atherosclerosis	0.000373	0.00198	CcSEcCtD
Naltrexone—Urticaria—Rosuvastatin—atherosclerosis	0.000371	0.00197	CcSEcCtD
Naltrexone—Oedema—Simvastatin—atherosclerosis	0.00037	0.00197	CcSEcCtD
Naltrexone—Anaphylactic shock—Simvastatin—atherosclerosis	0.00037	0.00197	CcSEcCtD
Naltrexone—Malaise—Pravastatin—atherosclerosis	0.00037	0.00196	CcSEcCtD
Naltrexone—Abdominal pain—Rosuvastatin—atherosclerosis	0.000369	0.00196	CcSEcCtD
Naltrexone—Palpitations—Niacin—atherosclerosis	0.000368	0.00196	CcSEcCtD
Naltrexone—Infection—Simvastatin—atherosclerosis	0.000368	0.00195	CcSEcCtD
Naltrexone—Loss of consciousness—Niacin—atherosclerosis	0.000366	0.00194	CcSEcCtD
Naltrexone—Cough—Niacin—atherosclerosis	0.000363	0.00193	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000361	0.00192	CcSEcCtD
Naltrexone—Insomnia—Lovastatin—atherosclerosis	0.000358	0.0019	CcSEcCtD
Naltrexone—Cough—Pravastatin—atherosclerosis	0.000358	0.0019	CcSEcCtD
Naltrexone—Paraesthesia—Lovastatin—atherosclerosis	0.000355	0.00189	CcSEcCtD
Naltrexone—Arthralgia—Niacin—atherosclerosis	0.000355	0.00188	CcSEcCtD
Naltrexone—Myalgia—Niacin—atherosclerosis	0.000355	0.00188	CcSEcCtD
Naltrexone—Hypertension—Pravastatin—atherosclerosis	0.000354	0.00188	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000354	0.00188	CcSEcCtD
Naltrexone—Anorexia—Simvastatin—atherosclerosis	0.000353	0.00187	CcSEcCtD
Naltrexone—Dyspnoea—Lovastatin—atherosclerosis	0.000353	0.00187	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000352	0.00187	CcSEcCtD
Naltrexone—Insomnia—Ezetimibe—atherosclerosis	0.000351	0.00187	CcSEcCtD
Naltrexone—Arthralgia—Pravastatin—atherosclerosis	0.000349	0.00185	CcSEcCtD
Naltrexone—Chest pain—Pravastatin—atherosclerosis	0.000349	0.00185	CcSEcCtD
Naltrexone—Myalgia—Pravastatin—atherosclerosis	0.000349	0.00185	CcSEcCtD
Naltrexone—Paraesthesia—Ezetimibe—atherosclerosis	0.000349	0.00185	CcSEcCtD
Naltrexone—Anxiety—Pravastatin—atherosclerosis	0.000348	0.00185	CcSEcCtD
Naltrexone—Dry mouth—Niacin—atherosclerosis	0.000347	0.00184	CcSEcCtD
Naltrexone—Dyspnoea—Ezetimibe—atherosclerosis	0.000346	0.00184	CcSEcCtD
Naltrexone—Discomfort—Pravastatin—atherosclerosis	0.000345	0.00183	CcSEcCtD
Naltrexone—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000344	0.00183	CcSEcCtD
Naltrexone—Decreased appetite—Lovastatin—atherosclerosis	0.000344	0.00183	CcSEcCtD
Naltrexone—Fatigue—Lovastatin—atherosclerosis	0.000341	0.00181	CcSEcCtD
Naltrexone—Oedema—Niacin—atherosclerosis	0.00034	0.00181	CcSEcCtD
Naltrexone—Anaphylactic shock—Niacin—atherosclerosis	0.00034	0.00181	CcSEcCtD
Naltrexone—Pain—Lovastatin—atherosclerosis	0.000338	0.0018	CcSEcCtD
Naltrexone—Constipation—Lovastatin—atherosclerosis	0.000338	0.0018	CcSEcCtD
Naltrexone—Confusional state—Pravastatin—atherosclerosis	0.000337	0.00179	CcSEcCtD
Naltrexone—Decreased appetite—Ezetimibe—atherosclerosis	0.000337	0.00179	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000337	0.00179	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000335	0.00178	CcSEcCtD
Naltrexone—Asthenia—Rosuvastatin—atherosclerosis	0.000335	0.00178	CcSEcCtD
Naltrexone—Insomnia—Simvastatin—atherosclerosis	0.000335	0.00178	CcSEcCtD
Naltrexone—Anaphylactic shock—Pravastatin—atherosclerosis	0.000335	0.00178	CcSEcCtD
Naltrexone—Oedema—Pravastatin—atherosclerosis	0.000335	0.00178	CcSEcCtD
Naltrexone—Fatigue—Ezetimibe—atherosclerosis	0.000335	0.00178	CcSEcCtD
Naltrexone—Shock—Niacin—atherosclerosis	0.000334	0.00178	CcSEcCtD
Naltrexone—Infection—Pravastatin—atherosclerosis	0.000332	0.00177	CcSEcCtD
Naltrexone—Paraesthesia—Simvastatin—atherosclerosis	0.000332	0.00177	CcSEcCtD
Naltrexone—Pain—Ezetimibe—atherosclerosis	0.000332	0.00176	CcSEcCtD
Naltrexone—Constipation—Ezetimibe—atherosclerosis	0.000332	0.00176	CcSEcCtD
Naltrexone—Tachycardia—Niacin—atherosclerosis	0.000332	0.00176	CcSEcCtD
Naltrexone—Pruritus—Rosuvastatin—atherosclerosis	0.00033	0.00176	CcSEcCtD
Naltrexone—Skin disorder—Niacin—atherosclerosis	0.00033	0.00175	CcSEcCtD
Naltrexone—Dyspnoea—Simvastatin—atherosclerosis	0.00033	0.00175	CcSEcCtD
Naltrexone—Hyperhidrosis—Niacin—atherosclerosis	0.000329	0.00175	CcSEcCtD
Naltrexone—Feeling abnormal—Lovastatin—atherosclerosis	0.000326	0.00173	CcSEcCtD
Naltrexone—Anorexia—Niacin—atherosclerosis	0.000324	0.00172	CcSEcCtD
Naltrexone—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000324	0.00172	CcSEcCtD
Naltrexone—Hyperhidrosis—Pravastatin—atherosclerosis	0.000323	0.00172	CcSEcCtD
Naltrexone—Decreased appetite—Simvastatin—atherosclerosis	0.000322	0.00171	CcSEcCtD
Naltrexone—Feeling abnormal—Ezetimibe—atherosclerosis	0.00032	0.0017	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00032	0.0017	CcSEcCtD
Naltrexone—Diarrhoea—Rosuvastatin—atherosclerosis	0.000319	0.0017	CcSEcCtD
Naltrexone—Fatigue—Simvastatin—atherosclerosis	0.000319	0.0017	CcSEcCtD
Naltrexone—Anorexia—Pravastatin—atherosclerosis	0.000319	0.0017	CcSEcCtD
Naltrexone—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000317	0.00169	CcSEcCtD
Naltrexone—Pain—Simvastatin—atherosclerosis	0.000317	0.00168	CcSEcCtD
Naltrexone—Constipation—Simvastatin—atherosclerosis	0.000317	0.00168	CcSEcCtD
Naltrexone—Urticaria—Lovastatin—atherosclerosis	0.000314	0.00167	CcSEcCtD
Naltrexone—Abdominal pain—Lovastatin—atherosclerosis	0.000313	0.00166	CcSEcCtD
Naltrexone—Body temperature increased—Lovastatin—atherosclerosis	0.000313	0.00166	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00031	0.00165	CcSEcCtD
Naltrexone—Dizziness—Rosuvastatin—atherosclerosis	0.000309	0.00164	CcSEcCtD
Naltrexone—Urticaria—Ezetimibe—atherosclerosis	0.000308	0.00164	CcSEcCtD
Naltrexone—Insomnia—Niacin—atherosclerosis	0.000307	0.00163	CcSEcCtD
Naltrexone—Abdominal pain—Ezetimibe—atherosclerosis	0.000307	0.00163	CcSEcCtD
Naltrexone—Body temperature increased—Ezetimibe—atherosclerosis	0.000307	0.00163	CcSEcCtD
Naltrexone—Paraesthesia—Niacin—atherosclerosis	0.000305	0.00162	CcSEcCtD
Naltrexone—Feeling abnormal—Simvastatin—atherosclerosis	0.000305	0.00162	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000305	0.00162	CcSEcCtD
Naltrexone—Dyspnoea—Niacin—atherosclerosis	0.000303	0.00161	CcSEcCtD
Naltrexone—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000303	0.00161	CcSEcCtD
Naltrexone—Insomnia—Pravastatin—atherosclerosis	0.000303	0.00161	CcSEcCtD
Naltrexone—Somnolence—Niacin—atherosclerosis	0.000302	0.00161	CcSEcCtD
Naltrexone—Paraesthesia—Pravastatin—atherosclerosis	0.0003	0.0016	CcSEcCtD
Naltrexone—Dyspnoea—Pravastatin—atherosclerosis	0.000298	0.00159	CcSEcCtD
Naltrexone—Decreased appetite—Niacin—atherosclerosis	0.000295	0.00157	CcSEcCtD
Naltrexone—Naloxone—ALB—atherosclerosis	0.000295	0.0888	CrCbGaD
Naltrexone—Rash—Rosuvastatin—atherosclerosis	0.000294	0.00156	CcSEcCtD
Naltrexone—Dermatitis—Rosuvastatin—atherosclerosis	0.000294	0.00156	CcSEcCtD
Naltrexone—Urticaria—Simvastatin—atherosclerosis	0.000294	0.00156	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Niacin—atherosclerosis	0.000293	0.00156	CcSEcCtD
Naltrexone—Abdominal pain—Simvastatin—atherosclerosis	0.000293	0.00155	CcSEcCtD
Naltrexone—Body temperature increased—Simvastatin—atherosclerosis	0.000293	0.00155	CcSEcCtD
Naltrexone—Headache—Rosuvastatin—atherosclerosis	0.000293	0.00155	CcSEcCtD
Naltrexone—Hypersensitivity—Lovastatin—atherosclerosis	0.000292	0.00155	CcSEcCtD
Naltrexone—Decreased appetite—Pravastatin—atherosclerosis	0.000291	0.00155	CcSEcCtD
Naltrexone—Pain—Niacin—atherosclerosis	0.000291	0.00154	CcSEcCtD
Naltrexone—Fatigue—Pravastatin—atherosclerosis	0.000289	0.00153	CcSEcCtD
Naltrexone—Pain—Pravastatin—atherosclerosis	0.000286	0.00152	CcSEcCtD
Naltrexone—Constipation—Pravastatin—atherosclerosis	0.000286	0.00152	CcSEcCtD
Naltrexone—Hypersensitivity—Ezetimibe—atherosclerosis	0.000286	0.00152	CcSEcCtD
Naltrexone—Asthenia—Lovastatin—atherosclerosis	0.000284	0.00151	CcSEcCtD
Naltrexone—Pruritus—Lovastatin—atherosclerosis	0.00028	0.00149	CcSEcCtD
Naltrexone—Asthenia—Ezetimibe—atherosclerosis	0.000278	0.00148	CcSEcCtD
Naltrexone—Gastrointestinal pain—Niacin—atherosclerosis	0.000278	0.00148	CcSEcCtD
Naltrexone—Nausea—Rosuvastatin—atherosclerosis	0.000277	0.00147	CcSEcCtD
Naltrexone—Feeling abnormal—Pravastatin—atherosclerosis	0.000276	0.00147	CcSEcCtD
Naltrexone—Pruritus—Ezetimibe—atherosclerosis	0.000275	0.00146	CcSEcCtD
Naltrexone—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000274	0.00145	CcSEcCtD
Naltrexone—Hypersensitivity—Simvastatin—atherosclerosis	0.000273	0.00145	CcSEcCtD
Naltrexone—Diarrhoea—Lovastatin—atherosclerosis	0.000271	0.00144	CcSEcCtD
Naltrexone—Urticaria—Niacin—atherosclerosis	0.00027	0.00143	CcSEcCtD
Naltrexone—Abdominal pain—Niacin—atherosclerosis	0.000269	0.00143	CcSEcCtD
Naltrexone—Body temperature increased—Niacin—atherosclerosis	0.000269	0.00143	CcSEcCtD
Naltrexone—Urticaria—Pravastatin—atherosclerosis	0.000266	0.00141	CcSEcCtD
Naltrexone—Asthenia—Simvastatin—atherosclerosis	0.000266	0.00141	CcSEcCtD
Naltrexone—Diarrhoea—Ezetimibe—atherosclerosis	0.000266	0.00141	CcSEcCtD
Naltrexone—Abdominal pain—Pravastatin—atherosclerosis	0.000265	0.00141	CcSEcCtD
Naltrexone—Body temperature increased—Pravastatin—atherosclerosis	0.000265	0.00141	CcSEcCtD
Naltrexone—Pruritus—Simvastatin—atherosclerosis	0.000262	0.00139	CcSEcCtD
Naltrexone—Dizziness—Lovastatin—atherosclerosis	0.000262	0.00139	CcSEcCtD
Naltrexone—Dizziness—Ezetimibe—atherosclerosis	0.000257	0.00136	CcSEcCtD
Naltrexone—Diarrhoea—Simvastatin—atherosclerosis	0.000253	0.00135	CcSEcCtD
Naltrexone—Vomiting—Lovastatin—atherosclerosis	0.000252	0.00134	CcSEcCtD
Naltrexone—Hypersensitivity—Niacin—atherosclerosis	0.00025	0.00133	CcSEcCtD
Naltrexone—Rash—Lovastatin—atherosclerosis	0.00025	0.00133	CcSEcCtD
Naltrexone—Dermatitis—Lovastatin—atherosclerosis	0.000249	0.00132	CcSEcCtD
Naltrexone—Headache—Lovastatin—atherosclerosis	0.000248	0.00132	CcSEcCtD
Naltrexone—Vomiting—Ezetimibe—atherosclerosis	0.000247	0.00131	CcSEcCtD
Naltrexone—Hypersensitivity—Pravastatin—atherosclerosis	0.000247	0.00131	CcSEcCtD
Naltrexone—Dizziness—Simvastatin—atherosclerosis	0.000245	0.0013	CcSEcCtD
Naltrexone—Rash—Ezetimibe—atherosclerosis	0.000245	0.0013	CcSEcCtD
Naltrexone—Dermatitis—Ezetimibe—atherosclerosis	0.000244	0.0013	CcSEcCtD
Naltrexone—Asthenia—Niacin—atherosclerosis	0.000244	0.0013	CcSEcCtD
Naltrexone—Headache—Ezetimibe—atherosclerosis	0.000243	0.00129	CcSEcCtD
Naltrexone—Pruritus—Niacin—atherosclerosis	0.00024	0.00128	CcSEcCtD
Naltrexone—Asthenia—Pravastatin—atherosclerosis	0.00024	0.00128	CcSEcCtD
Naltrexone—Pruritus—Pravastatin—atherosclerosis	0.000237	0.00126	CcSEcCtD
Naltrexone—Vomiting—Simvastatin—atherosclerosis	0.000235	0.00125	CcSEcCtD
Naltrexone—Nausea—Lovastatin—atherosclerosis	0.000235	0.00125	CcSEcCtD
Naltrexone—Rash—Simvastatin—atherosclerosis	0.000233	0.00124	CcSEcCtD
Naltrexone—Dermatitis—Simvastatin—atherosclerosis	0.000233	0.00124	CcSEcCtD
Naltrexone—Diarrhoea—Niacin—atherosclerosis	0.000233	0.00124	CcSEcCtD
Naltrexone—Headache—Simvastatin—atherosclerosis	0.000232	0.00123	CcSEcCtD
Naltrexone—Nausea—Ezetimibe—atherosclerosis	0.000231	0.00123	CcSEcCtD
Naltrexone—Diarrhoea—Pravastatin—atherosclerosis	0.000229	0.00122	CcSEcCtD
Naltrexone—Dizziness—Niacin—atherosclerosis	0.000225	0.00119	CcSEcCtD
Naltrexone—Dizziness—Pravastatin—atherosclerosis	0.000221	0.00118	CcSEcCtD
Naltrexone—Nausea—Simvastatin—atherosclerosis	0.00022	0.00117	CcSEcCtD
Naltrexone—Vomiting—Niacin—atherosclerosis	0.000216	0.00115	CcSEcCtD
Naltrexone—Rash—Niacin—atherosclerosis	0.000214	0.00114	CcSEcCtD
Naltrexone—Dermatitis—Niacin—atherosclerosis	0.000214	0.00114	CcSEcCtD
Naltrexone—Headache—Niacin—atherosclerosis	0.000213	0.00113	CcSEcCtD
Naltrexone—Vomiting—Pravastatin—atherosclerosis	0.000213	0.00113	CcSEcCtD
Naltrexone—Rash—Pravastatin—atherosclerosis	0.000211	0.00112	CcSEcCtD
Naltrexone—Dermatitis—Pravastatin—atherosclerosis	0.000211	0.00112	CcSEcCtD
Naltrexone—Headache—Pravastatin—atherosclerosis	0.00021	0.00111	CcSEcCtD
Naltrexone—Nausea—Niacin—atherosclerosis	0.000202	0.00107	CcSEcCtD
Naltrexone—Nausea—Pravastatin—atherosclerosis	0.000199	0.00106	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—GHRL—atherosclerosis	3.49e-05	0.000464	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PLAT—atherosclerosis	3.49e-05	0.000464	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL3—atherosclerosis	3.47e-05	0.000461	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SCARB1—atherosclerosis	3.44e-05	0.000457	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CNR2—atherosclerosis	3.41e-05	0.000454	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCL8—atherosclerosis	3.41e-05	0.000453	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MMP3—atherosclerosis	3.4e-05	0.000452	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PRKCG—atherosclerosis	3.36e-05	0.000447	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—F2—atherosclerosis	3.35e-05	0.000445	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NCF1—atherosclerosis	3.32e-05	0.000442	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HMGCR—atherosclerosis	3.24e-05	0.000431	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EDN1—atherosclerosis	3.24e-05	0.00043	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—F2—atherosclerosis	3.24e-05	0.00043	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—atherosclerosis	3.22e-05	0.000427	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL5—atherosclerosis	3.21e-05	0.000427	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CG—atherosclerosis	3.21e-05	0.000426	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AGT—atherosclerosis	3.18e-05	0.000423	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR2—atherosclerosis	3.14e-05	0.000417	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EDNRA—atherosclerosis	3.14e-05	0.000417	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CYBA—atherosclerosis	3.13e-05	0.000415	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—PLAT—atherosclerosis	3.1e-05	0.000412	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CG—atherosclerosis	3.1e-05	0.000412	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KNG1—atherosclerosis	3.06e-05	0.000407	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PLAT—atherosclerosis	3.06e-05	0.000407	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PARP1—atherosclerosis	3.06e-05	0.000407	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GHRL—atherosclerosis	3.06e-05	0.000407	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PRKCG—atherosclerosis	3.05e-05	0.000406	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AGTR1—atherosclerosis	3.04e-05	0.000405	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VWF—atherosclerosis	3.04e-05	0.000404	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOC3—atherosclerosis	3.02e-05	0.000402	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LDLR—atherosclerosis	3e-05	0.000399	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL2—atherosclerosis	2.99e-05	0.000397	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PLG—atherosclerosis	2.97e-05	0.000394	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AGT—atherosclerosis	2.96e-05	0.000393	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—F2—atherosclerosis	2.94e-05	0.000391	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL3—atherosclerosis	2.93e-05	0.00039	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ABCA1—atherosclerosis	2.89e-05	0.000384	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCG1—atherosclerosis	2.83e-05	0.000377	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CG—atherosclerosis	2.81e-05	0.000374	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NCF1—atherosclerosis	2.81e-05	0.000373	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SOCS3—atherosclerosis	2.81e-05	0.000373	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—atherosclerosis	2.79e-05	0.000371	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atherosclerosis	2.74e-05	0.000365	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—F2—atherosclerosis	2.73e-05	0.000363	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP3—atherosclerosis	2.71e-05	0.000361	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF2—atherosclerosis	2.7e-05	0.000359	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AGT—atherosclerosis	2.69e-05	0.000357	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KNG1—atherosclerosis	2.69e-05	0.000357	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AGTR1—atherosclerosis	2.67e-05	0.000355	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—FABP4—atherosclerosis	2.66e-05	0.000354	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LCAT—atherosclerosis	2.66e-05	0.000354	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR2—atherosclerosis	2.65e-05	0.000353	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EDNRA—atherosclerosis	2.65e-05	0.000353	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CYBA—atherosclerosis	2.64e-05	0.000351	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—PLG—atherosclerosis	2.63e-05	0.00035	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOB—atherosclerosis	2.62e-05	0.000349	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL2—atherosclerosis	2.62e-05	0.000348	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CG—atherosclerosis	2.62e-05	0.000348	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOA4—atherosclerosis	2.61e-05	0.000348	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PLG—atherosclerosis	2.6e-05	0.000346	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL8—atherosclerosis	2.6e-05	0.000346	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GHRL—atherosclerosis	2.59e-05	0.000344	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PARP1—atherosclerosis	2.59e-05	0.000344	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PLAT—atherosclerosis	2.59e-05	0.000344	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EDN1—atherosclerosis	2.58e-05	0.000343	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP7A1—atherosclerosis	2.57e-05	0.000342	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL5—atherosclerosis	2.56e-05	0.00034	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—atherosclerosis	2.53e-05	0.000337	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LPL—atherosclerosis	2.5e-05	0.000333	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—F2—atherosclerosis	2.48e-05	0.00033	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HMOX1—atherosclerosis	2.48e-05	0.00033	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SOCS3—atherosclerosis	2.46e-05	0.000327	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PRKCG—atherosclerosis	2.43e-05	0.000324	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—HMOX1—atherosclerosis	2.43e-05	0.000323	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—atherosclerosis	2.4e-05	0.000318	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP3—atherosclerosis	2.38e-05	0.000316	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOB—atherosclerosis	2.38e-05	0.000316	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CG—atherosclerosis	2.38e-05	0.000316	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP27A1—atherosclerosis	2.37e-05	0.000316	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SPP1—atherosclerosis	2.37e-05	0.000315	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF2—atherosclerosis	2.37e-05	0.000315	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL8—atherosclerosis	2.36e-05	0.000314	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—APOB—atherosclerosis	2.33e-05	0.000309	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—atherosclerosis	2.32e-05	0.000309	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTM1—atherosclerosis	2.31e-05	0.000307	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOB—atherosclerosis	2.3e-05	0.000306	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL8—atherosclerosis	2.28e-05	0.000303	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KNG1—atherosclerosis	2.27e-05	0.000302	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—LPL—atherosclerosis	2.27e-05	0.000302	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EDN1—atherosclerosis	2.26e-05	0.000301	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AGTR1—atherosclerosis	2.26e-05	0.0003	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALOX5AP—atherosclerosis	2.25e-05	0.000299	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOA2—atherosclerosis	2.25e-05	0.000299	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALOX15—atherosclerosis	2.25e-05	0.000299	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLA2G2A—atherosclerosis	2.25e-05	0.000299	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL5—atherosclerosis	2.25e-05	0.000298	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCG5—atherosclerosis	2.22e-05	0.000296	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GPX1—atherosclerosis	2.21e-05	0.000294	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL2—atherosclerosis	2.21e-05	0.000294	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PLG—atherosclerosis	2.2e-05	0.000292	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LPL—atherosclerosis	2.2e-05	0.000292	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PDGFB—atherosclerosis	2.19e-05	0.000292	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atherosclerosis	2.17e-05	0.000289	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CD36—atherosclerosis	2.16e-05	0.000287	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LPA—atherosclerosis	2.15e-05	0.000285	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AGT—atherosclerosis	2.14e-05	0.000285	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PRKCG—atherosclerosis	2.13e-05	0.000284	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LEP—atherosclerosis	2.1e-05	0.000279	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOE—atherosclerosis	2.1e-05	0.000279	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SOCS3—atherosclerosis	2.08e-05	0.000277	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—BGN—atherosclerosis	2.08e-05	0.000276	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SPP1—atherosclerosis	2.08e-05	0.000276	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CAV1—atherosclerosis	2.08e-05	0.000276	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOA1—atherosclerosis	2.07e-05	0.000276	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL8—atherosclerosis	2.07e-05	0.000275	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOA5—atherosclerosis	2.06e-05	0.000274	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—atherosclerosis	2.04e-05	0.000272	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP3—atherosclerosis	2.01e-05	0.000267	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARA—atherosclerosis	2e-05	0.000266	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ESR1—atherosclerosis	2e-05	0.000266	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF2—atherosclerosis	2e-05	0.000266	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLA2G1B—atherosclerosis	1.98e-05	0.000263	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—F2—atherosclerosis	1.98e-05	0.000263	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—PPARA—atherosclerosis	1.96e-05	0.000261	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOB—atherosclerosis	1.94e-05	0.000258	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AGT—atherosclerosis	1.94e-05	0.000258	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—atherosclerosis	1.93e-05	0.000256	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PDGFB—atherosclerosis	1.92e-05	0.000256	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALOX5—atherosclerosis	1.91e-05	0.000254	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EDN1—atherosclerosis	1.91e-05	0.000254	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOE—atherosclerosis	1.9e-05	0.000253	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL5—atherosclerosis	1.9e-05	0.000252	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CG—atherosclerosis	1.89e-05	0.000252	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CAV1—atherosclerosis	1.88e-05	0.000251	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOA1—atherosclerosis	1.88e-05	0.00025	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AGT—atherosclerosis	1.88e-05	0.00025	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LPL—atherosclerosis	1.86e-05	0.000247	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—APOA1—atherosclerosis	1.84e-05	0.000245	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LEP—atherosclerosis	1.84e-05	0.000245	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOE—atherosclerosis	1.84e-05	0.000245	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CAV1—atherosclerosis	1.82e-05	0.000242	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOA1—atherosclerosis	1.82e-05	0.000242	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK3—atherosclerosis	1.81e-05	0.000241	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PRKCG—atherosclerosis	1.8e-05	0.00024	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—INS—atherosclerosis	1.79e-05	0.000238	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL2—atherosclerosis	1.76e-05	0.000235	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SPP1—atherosclerosis	1.76e-05	0.000234	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ESR1—atherosclerosis	1.76e-05	0.000234	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—atherosclerosis	1.75e-05	0.000233	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—F2—atherosclerosis	1.74e-05	0.000231	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1—atherosclerosis	1.73e-05	0.000231	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CG—atherosclerosis	1.72e-05	0.000228	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NAMPT—atherosclerosis	1.72e-05	0.000228	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LIPC—atherosclerosis	1.71e-05	0.000227	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOC3—atherosclerosis	1.7e-05	0.000225	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LDLR—atherosclerosis	1.69e-05	0.000224	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CG—atherosclerosis	1.66e-05	0.000221	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARG—atherosclerosis	1.66e-05	0.00022	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SERPINE1—atherosclerosis	1.65e-05	0.000219	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CETP—atherosclerosis	1.65e-05	0.000219	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PDGFB—atherosclerosis	1.63e-05	0.000216	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—INS—atherosclerosis	1.63e-05	0.000216	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	1.62e-05	0.000215	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK3—atherosclerosis	1.59e-05	0.000211	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AGT—atherosclerosis	1.59e-05	0.000211	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SCARB1—atherosclerosis	1.58e-05	0.00021	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOS3—atherosclerosis	1.57e-05	0.000209	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—INS—atherosclerosis	1.57e-05	0.000209	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOE—atherosclerosis	1.56e-05	0.000207	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LEP—atherosclerosis	1.56e-05	0.000207	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL2—atherosclerosis	1.55e-05	0.000206	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CAV1—atherosclerosis	1.54e-05	0.000205	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOA1—atherosclerosis	1.54e-05	0.000204	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1—atherosclerosis	1.52e-05	0.000202	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—atherosclerosis	1.49e-05	0.000198	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMGCR—atherosclerosis	1.49e-05	0.000198	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ESR1—atherosclerosis	1.48e-05	0.000197	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—F2—atherosclerosis	1.47e-05	0.000195	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—atherosclerosis	1.46e-05	0.000194	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SERPINE1—atherosclerosis	1.44e-05	0.000192	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NOS3—atherosclerosis	1.43e-05	0.000189	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CG—atherosclerosis	1.4e-05	0.000187	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—atherosclerosis	1.39e-05	0.000185	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOS3—atherosclerosis	1.38e-05	0.000183	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—atherosclerosis	1.35e-05	0.000179	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK3—atherosclerosis	1.34e-05	0.000179	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—INS—atherosclerosis	1.33e-05	0.000177	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCA1—atherosclerosis	1.33e-05	0.000176	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—atherosclerosis	1.33e-05	0.000176	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL2—atherosclerosis	1.31e-05	0.000174	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—atherosclerosis	1.3e-05	0.000173	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1—atherosclerosis	1.29e-05	0.000171	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—atherosclerosis	1.26e-05	0.000168	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NFKB1—atherosclerosis	1.25e-05	0.000166	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK8—atherosclerosis	1.23e-05	0.000163	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—atherosclerosis	1.22e-05	0.000163	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—atherosclerosis	1.22e-05	0.000163	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SERPINE1—atherosclerosis	1.22e-05	0.000162	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—atherosclerosis	1.18e-05	0.000157	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOS3—atherosclerosis	1.17e-05	0.000155	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—atherosclerosis	1.16e-05	0.000155	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMOX1—atherosclerosis	1.14e-05	0.000151	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—atherosclerosis	1.13e-05	0.000151	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—atherosclerosis	1.12e-05	0.000149	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—atherosclerosis	1.11e-05	0.000147	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NFKB1—atherosclerosis	1.09e-05	0.000145	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOB—atherosclerosis	1.09e-05	0.000145	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK8—atherosclerosis	1.08e-05	0.000143	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—atherosclerosis	1.07e-05	0.000143	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK3—atherosclerosis	1.07e-05	0.000142	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—atherosclerosis	1.06e-05	0.000141	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LPL—atherosclerosis	1.04e-05	0.000138	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFB1—atherosclerosis	1.04e-05	0.000138	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—atherosclerosis	1.03e-05	0.000137	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPX1—atherosclerosis	1.02e-05	0.000135	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—atherosclerosis	9.98e-06	0.000133	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—atherosclerosis	9.93e-06	0.000132	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CD36—atherosclerosis	9.89e-06	0.000131	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—atherosclerosis	9.84e-06	0.000131	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—atherosclerosis	9.83e-06	0.000131	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK3—atherosclerosis	9.4e-06	0.000125	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—atherosclerosis	9.37e-06	0.000125	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—atherosclerosis	9.35e-06	0.000124	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NFKB1—atherosclerosis	9.25e-06	0.000123	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARA—atherosclerosis	9.2e-06	0.000122	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFB1—atherosclerosis	9.12e-06	0.000121	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK8—atherosclerosis	9.09e-06	0.000121	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—atherosclerosis	9.07e-06	0.000121	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AGT—atherosclerosis	8.91e-06	0.000118	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOE—atherosclerosis	8.73e-06	0.000116	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CAV1—atherosclerosis	8.65e-06	0.000115	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOA1—atherosclerosis	8.63e-06	0.000115	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—atherosclerosis	8.39e-06	0.000112	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—atherosclerosis	8.31e-06	0.000111	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK3—atherosclerosis	7.94e-06	0.000106	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CG—atherosclerosis	7.88e-06	0.000105	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—atherosclerosis	7.83e-06	0.000104	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFB1—atherosclerosis	7.71e-06	0.000102	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARG—atherosclerosis	7.6e-06	0.000101	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—INS—atherosclerosis	7.45e-06	9.91e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—atherosclerosis	7.23e-06	9.61e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—atherosclerosis	6.87e-06	9.13e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—atherosclerosis	6.83e-06	9.09e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—atherosclerosis	6.55e-06	8.71e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NOS3—atherosclerosis	6.54e-06	8.69e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—atherosclerosis	6.34e-06	8.43e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—atherosclerosis	5.98e-06	7.95e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—atherosclerosis	5.81e-06	7.72e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—atherosclerosis	5.36e-06	7.12e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—atherosclerosis	3.01e-06	3.99e-05	CbGpPWpGaD
